PubMed Health⌕ Search

Biomedical subjects

G Vacha

Publications and source records attributed to G Vacha.

12 recordsLinked to original sources

[20 years' experience with "difficult" vascular access].

The increased survival of patients in dialysis and the gradual increase in the age of uremic patients commencing chronic dialysis raises serious problems for the creation and maintenance of efficient vascular access. In cases in which it is extremely difficult to create arteriovenous fistulas (AVF) using existing upper limb veins, it is possible to resort to vascular grafts, lower limb AVF, central venous catheters or refer the patients for peritoneal dialysis if this method is technically possible. In order to evaluate the incidence of these phenomena in quantitative terms, the authors have made a retrospective analysis of patients undergoing vascular access surgery since the opening of the Dialysis Centre on 1/9/1973 to 30/9/1996. During this period (277 months) a total of 1,037 AVF implant operations were performed (in addition to 65 arteriovenous shunts in the earlier period and 28 permanent central venous catheters in the last 10 years). The survival of AVF grafts was lower than that in natural vessels in 384 patients without clinical risk. In diabetic subjects, those suffering from vascular pathologies, systemic diseases, or aged over 70, the survival of AVF was distinctly lower compared to the group without these risk factors. However, the higher risk group did not show any marked difference in survival between AVF in the patient's own veins and grafts. In only 4 out of 1,037 operations it was impossible to obtain vascular access in the upper limbs (2 patients were referred for peritoneal dialysis and AVF were executed in the thigh in 2 patients). In conclusion, the retrospective analysis of this series leads the authors to affirm that the rational use of natural vascular accesses normally allows a sufficient operating margin; however, in special cases suitable techniques (such as permanent central venous catheter or AVF in the thigh) can enable difficult situations to be resolved as an alternative to peritoneal dialysis.

Arteriovenous Shunt, Surgical↗

Drug treatment of hypertriglyceridaemia in chronic uraemic patients: preliminary report on D,L-carnitine and thiadenol.

Clofibrate (a very effective lipid-lowering drug) may cause serious muscular damage in uraemic patients, even if used at appropriately low dose. Some authors have reported that D,L-Carnitine and Thiadenol can reduce lipid levels in non uraemic subjects, without adverse effects. In our study D,L-Carnitine and Thiadenol were administered for 3 months to respectively 21 and 15 patients on chronic haemodialysis with hypertriglyceridaemia. With D,L-Carnitine 52% of patients showed lower plasma triglycerides (TG) (-40.6%, p less than 0.002); after Thiadenol 66.6% of patients showed reduced plasma TG concentration (-42.9%, p less than 0.001). No dietary changes were recorded during the study. No major side effects nor biochemical changes were observed. D,L-Carnitine and Thiadenol appear to be less effective, but also less dangerous than Clofibrate in chronic uraemic patients.

Carnitine↗

RDT with acetate-free bicarbonate buffered dialysis fluid: long-term effects on lipid pattern, acid-base balance and oxygen delivery.

Thirteen uraemic patients with hypertriglyceridaemia were treated for 9 months with acetate-free, bicarbonate containing dialysis fluid. With this treatment more physiological correction of acid-base balance and better tissue oxygenation were obtained. This fact can explain the better tolerance to treatment we have seen. In 9 of these patients triglyceride levels fell significantly on bicarbonate treatment; they shifted back to higher values after return to acetate dialysis. No changes were found in the other 4 patients.

Acetates↗

[14 years' experience with large-surface-area dialyzers].

Hemodialysis treatments with large surface area dialyzers were introduced in our dialysis unit since 1974. 129 uremic subjects were treated between September 1974 and August 1988. Age at start of high efficiency therapy ranged between 16 and 72 years; patients survival was: 95.3% at 1 year, 78.3% at 5 years, 65.8% at 10 years. At present 48 subjects are treated with this schedule. The key technical elements for implementation of such program include: high blood flow rates (greater than 300 ml/min), high surface area dialyzers (greater than 1.8 m2), bicarbonate as the buffer source. Traditionally, the rate of ultrafiltration was controlled by monitoring the TMP and the patients body weight, but in some case a preferred approach is the use of an automatic ultrafiltration control system. We conclude that, in a quite large dialysis population, an individualized short dialysis schedule may be safely applied for long time periods.

Adolescent↗